NOVAVAX vaccine approved for use in 12-17 year olds in South Korea

Trending News ☀️

This is great news for Novavax ($NASDAQ:NVAX), as their COVID-19 vaccine has now been approved for use in teenagers aged 12 to 17 years in South Korea. This expanded approval is thanks to their partner, SK biosciences, who got a post approval change application nod from the Korean Ministry of Food and Drug Safety. This is sure to help Novavax’s market and earnings in the long term, as they will now be able to provide their vaccine to an even larger population.

Market Reaction

On Friday, NOVAVAX stock opened at $41.2 and closed at $41.5, up by 2.8% from prior closing price of 40.3.

VI Analysis

Companies that have strong fundamentals are usually reflective of their long term potential. The following analysis on NOVAVAX is made simple by VI app. Based on VI Star Chart, NOVAVAX is strong in growth, medium in asset and weak in dividend, profitability. NOVAVAX has a low health score of 2/10 considering its cashflows and debt, is less likely to safely ride out any crisis without the risk of bankruptcy. NOVAVAX is classified as a ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. High growth companies are deemed more volatile as they attempt to grow faster.

Summary

This is a positive development for the company, and investors should consider buying shares in NOVAVAX as the company continues to make progress with its vaccine program.